Glenmark's monoclonal antibody for pain entering human trials

Glenmark Pharmaceuticals today said its novel monoclonal antibody for potential treatment of chronic pain is entering human trials.

The company has completed preclinical studies and Phase 1 enabling preclinical development programme for GBR 900; it has filed a Phase I clinical trial application with the MHRA, UK, Glenmark Pharma said in a BSE filing.

GBR 900 is a monoclonal antibody for the treatment of chronic pain targeting TrkA, the receptor of nerve growth factor (NGF).

The company said this is the first anti-TrkA monoclonal antibody to enter clinical development.

Glenmark Pharmaceuticals Ltd President of Biologics and Chief Scientific Officer Michael Buschle said: "We are very excited about the Phase I clinical study starting and expect that this study will extend the preclinical differentiation into a drug which will be clinically differentiated from anti-NGF antibodies.